Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance in vitro

Tang,Jingling; Ji,Hongyu; Ren,Jinmei; Li,Mengting; Zheng,Nannan; Wu,Linhua

doi:10.3892/ol.2016.5421

Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance in vitro

Authors:
- Jingling Tang
- Hongyu Ji
- Jinmei Ren
- Mengting Li
- Nannan Zheng
- Linhua Wu
View Affiliations

Affiliations: Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of Pharmacy, The Second Affiliated Hospital, Harbin Medical University, Key Laboratory of Medications Research, College of Heilongjiang Province, Harbin, Heilongjiang 150086, P.R. China
Published online on: November 23, 2016 https://doi.org/10.3892/ol.2016.5421
Pages: 389-395

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) is a main clinical hurdle for chemotherapy of cancer, and overexpression of P-glycoprotein (P-gp) is a key factor. In the present study, a new co‑delivery system for reversing MDR was designed and developed. The system was composed of curcumin (Cur) and piperine (Pip) encapsulated in solid lipid nanoparticles (SLNs) with tocopheryl polyethylene glycol succinate (TPGS) and Brij 78 [(Cur+Pip)‑SLNs]. TPGS and Brij 78 could sensitize MDR tumors by inhibiting the P‑gp drug efflux system. The combination of Cur and Pip, when administered in SLNs formulations, resulted in a significant enhancement in cytotoxicity and allowed efficient intracellular delivery of the drugs in drug‑resistant A2780/Taxol cells. This dual inhibitory strategy may have significant potential in the clinical management of MDR in cancer.

View Figures

View References

1	Fodale V, Pierobon M, Liotta L and Petricoin E: Mechanism of cell adaptation: When and how do cancer cells develop chemoresistance? Cancer J. 17:89–95. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kathawala RJ, Gupta P, Ashby CR Jr and Chen ZS: The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
3	Shapira A, Livney YD, Broxterman HJ and Assaraf YG: Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist Updat. 14:150–163. 2011. View Article : Google Scholar : PubMed/NCBI
4	Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: Problems and promises. Mol Pharm. 4:807–818. 2007. View Article : Google Scholar : PubMed/NCBI
5	Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005. View Article : Google Scholar : PubMed/NCBI
6	Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
7	Limtrakul P, Chearwae W, Shukla S, Phisalphong C and Ambudkar SV: Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem. 296:85–95. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV and Limtrakul P: Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol. 57:376–388. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ganta S and Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 6:928–939. 2009. View Article : Google Scholar : PubMed/NCBI
10	Romiti N, Tongiani R, Cervelli F and Chieli E: Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci. 62:2349–2358. 1998. View Article : Google Scholar : PubMed/NCBI
11	Bisht S, Feldmann G, Soni S, Ravi R, Karikar C and Maitra A and Maitra A: Polymeric nanoparticle-encapsulated curcumin (‘nanocurcumin’): A novel strategy for human cancer therapy. J Nanobiotechnology. 5:32007. View Article : Google Scholar : PubMed/NCBI
12	Maiti K, Mukherjee K, Gantait A, Saha BP and Mukherjee PK: Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 330:155–163. 2007. View Article : Google Scholar : PubMed/NCBI
13	Tiyaboonchai W, Tungpradit W and Plianbangchang P: Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 337:299–306. 2007. View Article : Google Scholar : PubMed/NCBI
14	Shaikh J, Ankola DD, Beniwal V, Singh D and Kumar MN: Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 37:223–230. 2009. View Article : Google Scholar : PubMed/NCBI
15	Shoba G, Joy D, Joseph T, Majeed M, Rajendran R and Srinivas PS: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64:353–356. 1998. View Article : Google Scholar : PubMed/NCBI
16	Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK and Fromm MF: Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 302:645–650. 2002. View Article : Google Scholar : PubMed/NCBI
17	Najar IA, Sachin BS, Sharma SC, Satti NK, Suri KA and Johri RK: Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res. 24:454–458. 2010. View Article : Google Scholar : PubMed/NCBI
18	Li S, Lei Y, Jia Y, Li N, Wink M and Ma Y: Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. Phytomedicine. 19:83–87. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kabanov AV, Batrakova EV and Alakhov VY: An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release. 91:75–83. 2003. View Article : Google Scholar : PubMed/NCBI
20	Batrakova EV, Li S, Brynskikh AM, Sharma AK, Li Y, Boska M, Gong N, Mosley RL, Alakhov VY, Gendelman HE and Kabanov AV: Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release. 143:290–301. 2010. View Article : Google Scholar : PubMed/NCBI
21	Guo Y, Luo J, Tan S, Otieno BO and Zhang Z: The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci. 49:175–186. 2013. View Article : Google Scholar : PubMed/NCBI
22	Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR and Mumper RJ: Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 69:3918–3926. 2009. View Article : Google Scholar : PubMed/NCBI
23	Tang J, Wang Y, Wang D, Wang Y, Xu Z, Racette K and Liu F: Key structure of brij for overcoming multidrug resistance in cancer. Biomacromolecules. 14:424–430. 2013. View Article : Google Scholar : PubMed/NCBI
24	Patel BD, Modi RV, Thakkar NA, Patel AA and Thakkar PH: Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene. J Pharm Bioallied Sci. 4:(Suppl 1). S14–S16. 2012. View Article : Google Scholar : PubMed/NCBI
25	Loveless VS, Surdock CP and Bhattacharjee H: Evaluation of zeta-potential and particle size of technetium 99mTc-sulfur colloid subsequent to the addition of lidocaine and sodium bicarbonate. J Nucl Med Technol. 38:49–52. 2010. View Article : Google Scholar : PubMed/NCBI
26	Yusuf M, Khan RA, Khan M and Ahmed B: Plausible antioxidant biomechanics and anticonvulsant pharmacological activity of brain-targeted β-carotene nanoparticles. Int J Nanomedicine. 7:4311–4321. 2012.PubMed/NCBI
27	Raghunand N, He X, Van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM and Gillies RJ: Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer. 80:1005–1011. 1999. View Article : Google Scholar : PubMed/NCBI
28	Singh DV, Godbole MM and Misra K: A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: Simulation for next generation of P-gp inhibitors. J Mol Model. 19:227–238. 2013. View Article : Google Scholar : PubMed/NCBI
29	Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
30	Eytan GD, Regev R, Oren G, Hurwitz CD and Assaraf YG: Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem. 248:104–112. 1997. View Article : Google Scholar : PubMed/NCBI
31	Tang J, Wang Y, Wang D, Xu Z, Racette K and Liu F: Key structure of brij for overcoming multidrug resistance in cancer. Biomacromolecules. 14:424–430. 2013. View Article : Google Scholar : PubMed/NCBI
32	Tang J, Fu Q, Wang Y, Racette K, Wang D and Liu F: Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Lett. 336:149–157. 2013. View Article : Google Scholar : PubMed/NCBI